NPY and cancer: In vitro and in vivo studies demonstrated that the optimized NPY conjugates were highly selective and effective in targeting cancer cells that overexpress NPY receptor, leading to increased uptake of boron-containing compounds and improved therapeutic efficacy in mouse models of cancer 86.